PET Radiotracers in Atherosclerosis: A Review

Blanchard, Isabella; Vootukuru, Nishita; Bhattaru, Abhijit; Patil, Shivaraj; Rojulpote, Chaitanya

doi:10.1016/j.cpcardiol.2023.101925

Cited by 2 publications

(1 citation statement)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, as previously reported, we observed no correlation of 18-FDG PET tracer uptake with cellular inflammation in SFA plaques (31), but we noted a trend toward increased uptake in fibroatheromas as compared to fibro-calcific plaques as identified by OCT. Other PET tracers might offer better characterization of LEAD plaques, but they were not available for human application at the time of initiation of our study. Gallium-68 DOTA-0-Tyr3-Octreotate (68Ga-DOTATATE) PET has shown potential in identifying vulnerable atherosclerotic plaques with high somatostatin receptor expression, while 11-carbon (11C)-choline and 18Ffluoromethylcholine (FMCH) tracers may improve the characterization of high-risk atherosclerotic plaques by detecting increased choline metabolism (32). These radiotracers might help to better characterize the pathogenesis of LEAD plaques and stratify the risk for adverse vascular limb events.…”

Section: Discussionmentioning

confidence: 99%

Simultaneous 18-FDG PET and MR imaging in lower extremity arterial disease

Koppara,

Dregely,

Nekolla

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundSimultaneous positron emission tomography (PET) and magnetic resonance imaging (MRI) is a novel hybrid imaging method integrating the advances of morphological tissue characterization of MRI with the pathophysiological insights of PET applications.AimThis study evaluated the use of simultaneous 18-FDG PET/MR imaging for characterizing atherosclerotic lesions in lower extremity arterial disease (LEAD).MethodsEight patients with symptomatic stenoses of the superficial femoral artery (SFA) under simultaneous acquisition of 18-FDG PET and contrast-enhanced MRI using an integrated whole-body PET/MRI scanner. Invasive plaque characterization of the SFA was performed by intravascular imaging using optical coherence tomography. Histological analysis of plaque specimens was performed after directional atherectomy.ResultsMRI showed contrast enhancement at the site of arterial stenosis, as assessed on T2-w and T1-w images, compared to a control area of the contralateral SFA (0.38 ± 0.15 cm vs. 0.23 ± 0.11 cm; 1.77 ± 0.19 vs. 1.57 ± 0.15; p-value <0.05). On PET imaging, uptake of 18F-FDG (target-to-background ratio TBR > 1) at the level of symptomatic stenosis was observed in all but one patient. Contrast medium-induced MR signal enhancement was detected in all plaques, whereas FDG uptake in PET imaging was increased in lesions with active fibroatheroma and reduced in fibrocalcified lesions.ConclusionIn this multimodal imaging study, we report the feasibility and challenges of simultaneous PET/MR imaging of LEAD, which might offer new perspectives for risk estimation.

show abstract

Section: Discussionmentioning

confidence: 99%

Simultaneous 18-FDG PET and MR imaging in lower extremity arterial disease

Koppara,

Dregely,

Nekolla

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

Emerging Trends and Innovations in the Treatment and Diagnosis of Atherosclerosis and Cardiovascular Disease: A Comprehensive Review towards Healthier Aging

Alradwan,

AL Fayez,

Alomary

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) are classed as diseases of aging, which are associated with an increased prevalence of atherosclerotic lesion formation caused by such diseases and is considered as one of the leading causes of death globally, representing a severe health crisis affecting the heart and blood vessels. Atherosclerosis is described as a chronic condition that can lead to myocardial infarction, ischemic cardiomyopathy, stroke, and peripheral arterial disease and to date, most pharmacological therapies mainly aim to control risk factors in patients with cardiovascular disease. Advances in transformative therapies and imaging diagnostics agents could shape the clinical applications of such approaches, including nanomedicine, biomaterials, immunotherapy, cell therapy, and gene therapy, which are emerging and likely to significantly impact CVD management in the coming decade. This review summarizes the current anti-atherosclerotic therapies’ major milestones, strengths, and limitations. It provides an overview of the recent discoveries and emerging technologies in nanomedicine, cell therapy, and gene and immune therapeutics that can revolutionize CVD clinical practice by steering it toward precision medicine. CVD-related clinical trials and promising pre-clinical strategies that would significantly impact patients with CVD are discussed. Here, we review these recent advances, highlighting key clinical opportunities in the rapidly emerging field of CVD medicine.

show abstract

PET Radiotracers in Atherosclerosis: A Review

Cited by 2 publications

References 109 publications

Simultaneous 18-FDG PET and MR imaging in lower extremity arterial disease

Simultaneous 18-FDG PET and MR imaging in lower extremity arterial disease

Emerging Trends and Innovations in the Treatment and Diagnosis of Atherosclerosis and Cardiovascular Disease: A Comprehensive Review towards Healthier Aging

Contact Info

Product

Resources

About